Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 24, Issue SUPPL.6, 2013, Pages

  Horwich, A ^a   Parker, C ^a   de Reijke, T ^b   Kataja, V ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; CABAZITAXEL; DENOSUMAB; DOCETAXEL; GONADORELIN AGONIST; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SAMARIUM 153; STRONTIUM 89; ZOLEDRONIC ACID;

ALOPECIA; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTICLE; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BONE SCINTISCANNING; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DIGITAL RECTAL EXAMINATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG TOLERANCE; DYSTROPHY; EDEMA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEVER; FOLLOW UP; GLEASON SCORE; HUMAN; HYPOCALCEMIA; IMAGE GUIDED BIOPSY; INTERMETHOD COMPARISON; JAPANESE; MULTIMODALITY CANCER THERAPY; MYALGIA; NEUROPATHY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS RADIOGRAPHY; PERIPHERAL EDEMA; PERSONALIZED MEDICINE; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; WATCHFUL WAITING;

BIOPSY; CHEMOTHERAPY, ADJUVANT; DIGITAL RECTAL EXAMINATION; EARLY DETECTION OF CANCER; EUROPE; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SCREENING; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK; RISK ASSESSMENT;

EID: 84885350053     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt208     Document Type: Article

References (59)

1. OECD/European Union. 'Cancer Incidence', in Health at a Glance: Europe 2010. OECD Publishing. 2010. http://dx.doi.org/10.1787/9789264090316-18-en.
2. Bray F, Lortet-Tieulent J, Ferlay J et al. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 2010; 46: 3040-3052.
3. Schroder FH, Hugosson J, Roobol MJ et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-990.
4. Andriole GL, Crawford ED, Grubb RL, III et al. Prostate cancer screening in the randomized prostate, lung, colorectal and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012; 104: 125-132.
5. Heijnsdijk EA, Wever EM, Auvinen A et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012; 367: 595-605.
6. Thompson IM, Ankerst DP, Chi C et al. Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst 2006; 98: 529-534.
7. Hessels D, van Gils MP, van Hooij O et al. Predictive value of PCA3 in urinary sediments in determining clinic-pathologic characteristics of prostate cancer. Prostate 2010; 70: 10-16.
8. Scattoni V, Zlotta A, Montironi R et al. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007; 52: 1309-1322.
9. Epstein JI, Allsbrook WC, Jr, Amin MB et al. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29: 1228-1242.
10. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974.
11. Shariat SF, Karakiewicz PI, Roehrborn CG et al. An updated catalog of prostate cancer predictive tools. Cancer 2008; 113: 3075-3099. Review.
12. Suardi N, Capitanio U, Chun FK et al. Currently used criteria for active surveillance in men with low-risk prostate cancer. An analysis of pathologic features. Cancer 2008; 113: 2068-2072.
13. O'Sullivan J, Norman AR, Cook GJ et al. Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital. BJU Int 2003; 92: 685-689.
14. Wilt TJ, Brawer MK, Jones KM et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203-213.
15. Bill-Axelson A, Holmberg L, Filén F et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008; 100: 1144-1154.
16. Steineck G, Helgesen F, Adolfsson J et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347: 790-796.
17. Johansson E, Bill-Axelson A, Holmberg L et al. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the randomized Scandinavian prostate cancer group study number 4 (SPCG-4) clinical trial. Eur Urol 2009; 55: 422-430.
18. Bolla M, Van Tienhoven G, Warde P et al. External irradiation with or without longterm androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010; 11: 1066-1073.
19. Widmark A, Klepp O, Solberg A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer: an open randomised phase III trial. Lancet 2009; 373: 301-308.
20. Warde P, Mason M, Ding K et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 378: 2104-2111.
21. Denham JW, Steigler A, Lamb DS et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised controlled trial. Lancet Oncol 2011; 12: 451-459.
22. D'Amico AV, Manola J, Loffredo M et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821-827.
23. Roach M, 3rd, Bae K, Speight J et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. JCO 2008; 26: 585-591.
24. Hanks GE, Pajak TF, Porter A et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21: 3972-3978.
25. Bolla M, de Reijke TM, Van Tienhoven G et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-2527.
26. Galvao DA, Taaffe DR, Spry N et al. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 2010; 28: 340-347.
27. McLeod DG, Iversen P, See WA et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97: 247-254.
28. Kunath F, Keck B, Antes G et al. Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review. BMC Med 2012; 10: 96.
29. Bolla M, van Poppel H, Tombal B et al. Postoperative radiotherapy after radical prostatectomy for high risk prostate cancer: long term results of a randomized controlled trial (EORTC trial 22911). Lancet 2012; 380: 2018-2027.
30. Thompson IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow up of a randomized clinical trial. J Urol 2009; 181: 956-962.
31. Trock BJ, Han M, Freedland SJ et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 2760-2769.
32. Niraula S, Le LW, Tannock IF. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol. 2013; 31: 2029-2036.
33. Moul JW, Wu H, Sun L et al. Early versus delayed hormonal therapy for prostate antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171: 1141-1147.
34. Crook JM, O'Callaghan CJ, Duncan G et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012; 367: 895-903.
35. Calais da Silva FE, Bono AV, Whelan P et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55: 1269-1277.
36. Hussain M, Tangen CM, Berry DL et al. Intermittent versus continuous androgen deprivation in prostate cancer. NEJM 2013; 368: 1314-1325.
37. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 1491-1498.
38. Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-1042.
39. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
40. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197.
41. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-148.
42. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
43. Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-245.
44. Petrylak DP, Tangen C, Hussain M et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
45. Kellokumpu-Lehtinen P-L, Harmenberg U, Joensuu T et al. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 2013: 14; 117-124.
46. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
47. Price P, Hoskin PJ, Easton D et al. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 1986; 6: 247-255.
48. Chow E, Harris K, Fan G et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 2007; 25: 1423-1436.
49. Quilty PM, Kirk D, Bolger JJ et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 33-40.
50. Porter AT, McEwan AJ, Powe JE et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805-813.
51. Serafini AN, Houston SJ, Resche I et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebocontrolled clinical trial. J Clin Oncol 1998; 16: 1574-1581.
52. Parker C, Heinrich D, O'Sullivan JM et al. Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). Eur J Cancer 2011; 47(Supp 2): 3.
53. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882.
54. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822.
55. Loblaw DA, Perry J, Chambers A et al. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario practice guidelines initiative's neuro-oncology disease site group. J Clin Oncol 2003; 23: 2028-2037.
56. Venkitaraman R, Sohaib SA, Barbachano Y et al. Detection of occult spinal cord compression with magnetic resonance imaging of the spine. Clin Oncol 2007; 19: 528-531.
57. Beltran H, Tagawa ST, Park K et al. Challenges in recognizing treatmentrelated neuroendocrine prostate cancer. J Clin Oncol 2012; 30: e386-389.
58. Doneux A, Parker CC, Norman A et al. The utility of digital rectal examination after radical radiotherapy for prostate cancer. Clin Oncol 2005; 17: 172-173.
59. Andreyev J. Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol 2007; 8: 1007-1017.